Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most general product facts and mechanism-style descriptions are consistent with the provided label excerpts, but multiple key label-specific items are incorrect or misaligned: the indicated age range is wrong (label: 6 years and older; claims: 12 years and older), and several dosing/administration details are omitted (prime/reprime, route, eye-avoidance, shake). Overall alignment is partial due to material age-indication error.
Category Scores
Accurate Statements
Dymista is a combination product containing azelastine hydrochloride and fluticasone propionate.
Drug/Active ingredient(s) provided; label context is consistent with DYMISTA containing azelastine hydrochloride and fluticasone propionate.
Dymista combines azelastine hydrochloride and fluticasone propionate.
Drug/Active ingredient(s) provided.
Azelastine hydrochloride is an antihistamine.
Not supported or contradicted by the supplied label excerpts.
Fluticasone propionate is a corticosteroid.
Warnings/precautions and interactions refer to fluticasone propionate as a corticosteroid (e.g., hypercorticism/adrenal suppression; use with CYP3A4 inhibitors).
The azelastine hydrochloride in Dymista blocks the action of histamine released during an allergic reaction.
Not supported or contradicted by the supplied label excerpts.
Fluticasone propionate reduces inflammation in the nasal passages.
Not supported or contradicted by the supplied label excerpts.
Dymista nasal spray has received FDA approval.
Not directly supported or contradicted by the supplied excerpts (approval status not stated in provided text).
Unsupported Statements
Dymista nasal spray has received FDA approval.
The provided label excerpts do not explicitly state approval status.
Azelastine hydrochloride is an antihistamine.
No antihistamine description is present in the supplied label excerpts.
The azelastine hydrochloride in Dymista blocks the action of histamine released during an allergic reaction.
No mechanism-of-action statement of histamine blockade is present in the supplied label excerpts.
Fluticasone propionate reduces inflammation in the nasal passages.
The supplied label excerpts discuss corticosteroid-related risks and interactions but do not describe anti-inflammatory effect wording.
Dymista is claimed to alleviate symptoms such as nasal congestion, runny nose, sneezing, and itchy nose associated with allergic rhinitis.
The provided indications excerpt specifies relief of symptoms of seasonal allergic rhinitis, but the specific symptom list (nasal congestion, runny nose, sneezing, itchy nose) is not explicitly present in the supplied excerpts.
Dymista is a combination product containing azelastine hydrochloride and fluticasone propionate.
While consistent with the provided drug ingredient section, explicit phrasing beyond the ingredient listing is not directly present in the supplied label excerpts.
Contradictions
High
AI Statement
Dymista is approved for the treatment of nasal allergy symptoms in patients 12 years of age and older.
Label Reference
Section 1 INDICATIONS AND USAGE: “DYMISTA is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.”
Important Omissions
Recommended dosage and administration instructions (1 spray per nostril twice daily; nasal route only; shake bottle; avoid spraying into eyes; prime before initial use with 6 sprays; reprime if not used for 14+ days).
Importance:
High
Medication safety/warnings relevant to safe use (somnolence/CNS depressant avoidance; local nasal effects like nasal ulceration/septal perforation; glaucoma/cataracts monitoring; immunosuppression/infection caution; adrenal suppression/hypercorticism risk; CYP3A4 inhibitors/ritonavir not recommended; pediatric growth monitoring).
Importance:
Moderate
Contraindication details (hypersensitivity to azelastine, fluticasone, or any other ingredients; include anaphylaxis as reactions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary safety concern is a material age-indication mismatch (claims restrict use to ≥12, whereas label indicates ≥6). Additionally, the response omits key administration and safety precautions that are material to correct and safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Incorrect labeled age indication (stated as ≥12 rather than label-supported ≥6).
Suggested Improvement
Replace the age claim with “6 years of age and older” and include label-specific dosing/administration details (1 spray in each nostril twice daily; shake; prime/reprime; nasal route; avoid eyes) plus key warnings/interaction precautions (e.g., avoid ritonavir/strong CYP3A4 inhibitors; somnolence/CNS depressants; pediatric growth monitoring).